Sell Ophthalmic Gene Therapy IND Checklist to NIH-Funded Startups
- Organization
- FDA's complex gene therapy regulatory pathway for ocular applications
- Sector
- NIH-funded ophthalmology gene therapy startups
- Location
- Location unspecified
Source reference
Executive summary
Current state
NIH awarded $311,049 Phase I STTR funding to OUTFLOWGEN LLC for a first-in-class CRISPR glaucoma therapy, creating a predictable commercial gap where scientific validation exists but commercialization infrastructure is absent. The structural asymmetry is between NIH's ability to fund early science and small biotechs' inability to navigate the regulatory and capital requirements for clinical development.
Market catalyst
NIH-funded gene therapy startups like OUTFLOWGEN have 'results intended to justify future IND-enabling studies' but lack concrete, actionable regulatory roadmaps. FDA guidance is generic; they need disease- and modality-specific navigation they cannot afford from expensive consultants.
This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.
Field notes
Intelligence ledger
Add new evidence, corrections, or practical context to this directive. Keep claims attributable to a source where possible.
Sign in to add intelligence or vote on a field note.
Field intel logs: [ 0 ] entries. No operative updates submitted for this directive. Submit intel to claim clearance.